7/19/2011

European regulators approved Amgen's Xgeva, or denosumab, for preventing fractures and other skeletal events in adults with solid tumors. The approval provides Amgen another year of market exclusivity. Denosumab also is marketed as Prolia for osteoporosis.

Full Story:
InPharm.com

Related Summaries